Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRDL NASDAQ:GOVX NASDAQ:VUZI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRDLCardiol Therapeutics$0.99-8.7%$1.36$0.77▼$2.63$89.29M1.05725,801 shs1.65 million shsGOVXGeoVax Labs$0.68+1.4%$0.83$0.43▼$11.18$10.66M3.271.47 million shs430,766 shsVUZIVuzix$2.07-1.4%$2.63$0.83▼$5.79$160.11M1.41.44 million shs1.10 million shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRDLCardiol Therapeutics+0.93%-27.52%-22.86%-6.09%-43.75%GOVXGeoVax Labs+1.30%-7.07%+3.30%-27.84%-62.39%VUZIVuzix-7.89%+4.48%-18.92%+8.25%+103.88%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRDLCardiol Therapeutics2.247 of 5 stars3.74.00.00.01.10.00.6GOVXGeoVax Labs2.4607 of 5 stars3.54.00.00.02.30.00.6VUZIVuzix0.2851 of 5 stars1.50.00.00.03.10.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRDLCardiol Therapeutics 3.33Buy$8.00711.44% UpsideGOVXGeoVax Labs 3.00Buy$8.881,207.07% UpsideVUZIVuzix 3.00Buy$2.00-3.38% DownsideCurrent Analyst Ratings BreakdownLatest VUZI, GOVX, and CRDL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/7/2025GOVXGeoVax LabsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.007/29/2025GOVXGeoVax LabsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.007/17/2025GOVXGeoVax LabsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.006/16/2025GOVXGeoVax LabsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.006/2/2025CRDLCardiol TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$9.00(Data available from 8/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRDLCardiol TherapeuticsN/AN/AN/AN/A$0.22 per shareN/AGOVXGeoVax Labs$3.95M2.74N/AN/A$0.18 per share3.77VUZIVuzix$5.76M27.40N/AN/A$0.51 per share4.06Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRDLCardiol Therapeutics-$26.77M-$0.34N/AN/AN/AN/A-209.63%-141.09%8/11/2025 (Estimated)GOVXGeoVax Labs-$24.99M-$2.01N/AN/AN/A-403.88%-408.80%-279.89%N/AVUZIVuzix-$73.54M-$1.03N/A∞N/A-1,352.74%-198.84%-185.84%8/14/2025 (Estimated)Latest VUZI, GOVX, and CRDL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025CRDLCardiol Therapeutics-$0.11N/AN/AN/AN/AN/A7/28/2025Q2 2025GOVXGeoVax Labs-$0.41-$0.35+$0.06-$0.35$0.37 million$0.85 million5/12/2025Q1 2025VUZIVuzix-$0.12-$0.11+$0.01-$0.11$1.34 million$1.58 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRDLCardiol TherapeuticsN/AN/AN/AN/AN/AGOVXGeoVax LabsN/AN/AN/AN/AN/AVUZIVuzixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRDLCardiol Therapeutics0.013.263.26GOVXGeoVax LabsN/A2.032.03VUZIVuzixN/A7.686.21Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRDLCardiol Therapeutics12.49%GOVXGeoVax Labs6.09%VUZIVuzix35.87%Insider OwnershipCompanyInsider OwnershipCRDLCardiol Therapeutics5.25%GOVXGeoVax Labs1.20%VUZIVuzix8.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRDLCardiol Therapeutics2082.68 million78.34 millionNot OptionableGOVXGeoVax Labs1015.93 million15.73 millionNot OptionableVUZIVuzix11076.24 million69.91 millionOptionableVUZI, GOVX, and CRDL HeadlinesRecent News About These CompaniesVuzix Announces New Board MemberAugust 7 at 8:50 AM | prnewswire.comVuzix stock surges after receiving six-figure smart glasses orderAugust 7 at 2:05 AM | investing.comVuzix Receives Six-Figure Smart Glasses Follow-on Order from LogistiVIEW to Support Fortune 100 Retail Customer DeploymentAugust 6 at 1:00 PM | prnewswire.comVuzix Corporation (NASDAQ:VUZI) Sees Large Increase in Short InterestAugust 3, 2025 | americanbankingnews.comVuzix Corporation (NASDAQ:VUZI) Short Interest Up 100,064.8% in JulyAugust 2, 2025 | marketbeat.comVuzix Schedules Conference Call to Discuss Second Quarter 2025 Financial Results and Business UpdateJuly 31, 2025 | prnewswire.comSkandinaviska Enskilda Banken AB publ Takes Position in Vuzix Corporation (NASDAQ:VUZI)July 31, 2025 | marketbeat.comVuzix Corporation's (NASDAQ:VUZI) largest shareholders are individual investors with 58% ownership, institutions own 26%July 21, 2025 | finance.yahoo.comVuzix, Ramblr Partner to Bring Advanced AI-Driven Intelligence to Enterprise Smart GlassesJuly 21, 2025 | msn.comVuzix (VUZI) Receives Follow-On Orders for Z100 Smart Glasses from TranscribeGlassJuly 12, 2025 | insidermonkey.comVuzix (NASDAQ:VUZI) Shares Pass Above 50-Day Moving Average - Should You Sell?July 8, 2025 | marketbeat.comMentra develops an open source operating system for smart glassesJuly 5, 2025 | heise.deHVuzix joins Russell 3000 Index, enhancing market visibilityJuly 2, 2025 | uk.investing.comSphere’s Spatial Computing Platform Now Available on Vuzix M-Series Smart GlassesJuly 1, 2025 | auganix.orgATranscribeGlass Places Multiple Follow-on Orders for Vuzix Z100 Smart GlassesJune 30, 2025 | prnewswire.comVuzix Confirms Addition to Russell 3000 and Russell 2000 IndexesJune 30, 2025 | prnewswire.comVuzix (VUZI) Doubles Down on AR and AI with Strategic Enterprise CollaborationsJune 28, 2025 | msn.comVuzix (VUZI) Receives $5 Million Investment from Quanta, Achieves Waveguide Production TargetsJune 24, 2025 | msn.comSphere Brings Its AI-Powered Mixed Reality to Vuzix Smart GlassesJune 24, 2025 | prnewswire.comVeo’s AI Video Memes, Vuzix Raises $5 Million, And More On AWE 2025June 20, 2025 | forbes.comVuzix Secures $5M Investment as Veteran Smart Glasses Maker Sets Sights on ConsumersJune 17, 2025 | roadtovr.comRNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVUZI, GOVX, and CRDL Company DescriptionsCardiol Therapeutics NASDAQ:CRDL$0.99 -0.09 (-8.71%) Closing price 04:00 PM EasternExtended Trading$0.98 -0.01 (-1.00%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.GeoVax Labs NASDAQ:GOVX$0.68 +0.01 (+1.43%) As of 04:00 PM EasternGeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.Vuzix NASDAQ:VUZI$2.07 -0.03 (-1.43%) Closing price 04:00 PM EasternExtended Trading$2.09 +0.02 (+1.01%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vuzix Corporation designs, manufactures, and markets smart glasses and augmented reality (AR) technologies and products for the enterprise, medical, defense, and consumer markets. The company's products include head-mounted smart personal display and wearable computing devices that offer users a portable viewing experience, provide solutions for mobility, wearable displays, and augmented reality, as well as original equipment manufacturer waveguide optical components and display engines. It also provides certified ERP SaaS logistics solution to support hand-held mobile phones and scanners used in logistics, warehousing, and manufacturing applications. It holds approximately 375 patents and patents pending and various IP licenses in the fields of optics, head-mounted displays, and augmented reality Video Eyewear field. It sells its products through resellers, distributors, direct to commercial customers, and online stores, as well as various Vuzix operated web stores in North America, Europe, the Asia-Pacific, and internationally. The company was formerly known as Icuiti Corporation and changed its name to Vuzix Corporation in September 2007. Vuzix Corporation was incorporated in 1997 and is headquartered in West Henrietta, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Airbnb Beats Earnings, But the Growth Story Is Losing Altitude Dutch Bros Just Flipped the Script With a Massive Earnings Beat Amazon Takes an Equity Stake in IonQ—Any Upside Potential? D-Wave Delivers Growth Shock—Investors Eye Quantum Future Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? Constellation Energy’s Earnings Beat Signals a New Era AppLovin’s Q2 Miss Spooks Market, But Wall Street Doubles Down DraftKings Posts Record Quarter, Eyes Profitability Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.